Canada markets open in 3 hours 22 minutes
  • S&P/TSX

    20,461.93
    +60.44 (+0.30%)
     
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • DOW

    34,764.82
    +506.50 (+1.48%)
     
  • CAD/USD

    0.7884
    -0.0018 (-0.23%)
     
  • CRUDE OIL

    73.34
    +0.04 (+0.05%)
     
  • BTC-CAD

    53,733.34
    -2,539.23 (-4.51%)
     
  • CMC Crypto 200

    1,046.87
    -62.06 (-5.60%)
     
  • GOLD FUTURES

    1,754.20
    +4.40 (+0.25%)
     
  • RUSSELL 2000

    2,259.04
    +40.48 (+1.82%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,212.75
    -90.75 (-0.59%)
     
  • VOLATILITY

    19.93
    -0.94 (-4.50%)
     
  • FTSE

    7,052.43
    -25.92 (-0.37%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • CAD/EUR

    0.6716
    -0.0011 (-0.16%)
     

FDA Clears Promega OncoMate™ MSI Dx Analysis System

·4 min read

Oncologists and pathologists in US can now use microsatellite instability (MSI) diagnostic to screen for Lynch syndrome in patients with colorectal cancer

MADISON, Wis., July 28, 2021--(BUSINESS WIRE)--Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer. The OncoMate™ MSI Dx Analysis System (OncoMate™ MSI), developed by Promega, has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors. This is the industry's first and only PCR-based diagnostic kit for MSI characterization that is FDA-cleared for use in labs across the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005823/en/

The OncoMate™ MSI Dx Analysis System developed by Promega has been cleared by the US Food and Drug Administration (FDA) as an in vitro diagnostic medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors. This is the industry's first and only PCR-based diagnostic kit for MSI characterization that is FDA-cleared for use in labs across the United States. (Photo: Business Wire)

Lynch Syndrome

Lynch syndrome is an inherited condition that increases the risk of developing colorectal and other cancers. It is the most common inherited cause of colorectal cancer. An estimated 1 in 279 people have Lynch syndrome but 95% do not know they have it. High-frequency MSI (MSI-H) is an indication that patients should be referred for further genetic testing for Lynch syndrome.

"Tools that enable the accurate determination of the MSI status of colorectal cancer tumors are vital for patients and their families," says James Eshleman, MD, PhD, Professor of Pathology and Oncology, Johns Hopkins University School of Medicine. "An FDA-cleared MSI diagnostic kit gives patients, oncologists, and pathologists in the U.S. access to technology that, for the last 15 years, has been a gold standard around the world for studying MSI status in solid tumors."

MSI Status

DNA is constantly copying itself. MSI is a form of genomic instability caused when too many or too few repeating bases, called microsatellites, occur during DNA replication and the body’s mismatch repair system fails to correct these errors. MSI status is used to screen for Lynch syndrome. Since Lynch syndrome is hereditary, this information is crucial not only for the patient, but for family members as well.

Universal screening of all colorectal tumors for MSI status is recommended in guidelines by the National Comprehensive Cancer Network (NCCN®) as well as the American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).

Promega OncoMate™ MSI Technology

Promega OncoMate™ MSI is based on the company’s "for research use only" technology, the first commercially manufactured kit to detect MSI status and the leading standard test for MSI status detection in research laboratories worldwide. Promega MSI technology has been used extensively in clinical research for more than 15 years and is supported by over 140 peer-reviewed publications.

The Promega five MSI loci are often the comparative benchmark used by other companies and organizations for determining MSI status and align with guidelines including the National Cancer Institute (NCI) – Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and Microsatellite Instability.

OncoMate™ MSI Features:

  • Fluorescent, multiplex PCR-based fragment-sizing test

  • High sensitivity and specificity – targets five mononucleotide repeat markers.

  • Short turn-around time – from FFPE sample to answer in as little as 10 hours.

  • Conserves precious samples – MSI results with ≤1 FFPE section.

Promega MSI Global IVD Portfolio

OncoMate™ MSI is CE-marked IVD medical device in the United Kingdom and select European countries. Promega also intends to seek regulatory clearance for a Promega MSI IVD in China where the Promega MSI technology received innovation status and priority review by the National Medical Products Administration (NMPA).

To learn more about the OncoMate™ MSI Dx Analysis System, visit: www.promega.com/OncoMateIVD

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit www.promega.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005823/en/

Contacts

Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting